Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank91
3Y CAGR+34.0%
5Y CAGR+21.3%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+34.0%/yr
vs +15.3%/yr prior
5Y CAGR
+21.3%/yr
Recent acceleration
Acceleration
+18.7pp
Accelerating
Percentile
P91
Near historical high
vs 5Y Ago
2.6x
Strong expansion
Streak
1 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| TTM | $209.56M | +0.5% |
| 2024 | $208.57M | -14.2% |
| 2023 | $243.19M | +179.2% |
| 2022 | $87.11M | +3.2% |
| 2021 | $84.39M | +5.7% |
| 2020 | $79.86M | +0.5% |
| 2019 | $79.43M | +61.0% |
| 2018 | $49.35M | +50.1% |
| 2017 | $32.88M | +23.9% |
| 2016 | $26.53M | - |